Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ISLAND PHARMACEUTICALS LIMITED
ABN	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Ntoumenopoulos
Date of last notice	5 November 2025

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Sobol Capital Pty Ltd ATF Sobol Capital Trust (Sole Director) Christopher Ntoumenopoulos & Leo Ntoumenopoulos ATF The Ntoumenopoulos Superannuation Fund (Trustee & Beneficiary)
Date of change	12 November 2025

No. of securities held prior to change Christopher Ntoumenopoulos Sobol Capital Pty Ltd ATF Sobol Capital Trust (Sole Director) Christopher Ntoumenopoulos & Leo Ntoumenopoulos ATF The Ntoumenopoulos Superannuation Fund (Trustee & Beneficiary)	• 2,000,000 options exercisable at $0.10 expiring 10 December 2027, vesting 50% on 10 December 2025 (12 months) and 50% on 10 December 2026 (24 months) • 714,286 fully paid ordinary shares • 357,143 options exercisable at $0.07 expiring 4 December 2025 • 357,143 options exercisable at $0.07 expiring 4 December 2026 • 1,321,516 fully paid ordinary shares • 487,425 options exercisable at $0.07 expiring 4 December 2025 • 487,425 options exercisable at $0.07 expiring 4 December 2026
Class	i) Options exercisable at $0.30 expiring 3 years from the Grant date (27 October 2028), vesting 50% on receipt of U.S. Food and Drug Administration approval for Galidesivir under the Animal Rule Pathway and 50% on issue of a Priority Review Voucher by the FDA in connection with such approval. ii) Options exercisable at $0.16, expiring on 30 April 2028, vesting 50% on 30 April 2026 and 50% on 30 April 2027.
Number acquired	i) 2,000.000 ii) 750,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	i) $200 ii) $75

+ See chapter 19 for defined terms.

No. of securities held after change Christopher Ntoumenopoulos	• 2,000,000 options exercisable at $0.10 expiring 10 December 2027, vesting 50% on 10 December 2025 (12 months) and 50% on 10 December 2026 (24 months) • 2,000,000 options exercisable at $0.30 expiring 3 years from the Grant date (27 October 2028), vesting 50% on receipt of U.S. Food and Drug Administration approval for Galidesivir under the Animal Rule Pathway and 50% on issue of a Priority Review Voucher by the FDA in connection with such approval. • 750,000 options exercisable at $0.16, expiring on 30 April 2028, vesting 50% on 30 April 2026 and 50% on 30 April 2027.
Sobol Capital Pty Ltd ATF Sobol Capital Trust (Sole Director)	• 714,286 fully paid ordinary shares • 357,143 options exercisable at $0.07 expiring 4 December 2025 • 357,143 options exercisable at $0.07 expiring 4 December 2026
Christopher Ntoumenopoulos & Leo Ntoumenopoulos ATF The Ntoumenopoulos Superannuation Fund (Trustee & Beneficiary)	• 1,321,516 fully paid ordinary shares • 487,425 options exercisable at $0.07 expiring 4 December 2025 • 487,425 options exercisable at $0.07 expiring 4 December 2026
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options approved by Shareholders at Annual General Meeting on 9 October 2025

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ISLAND PHARMACEUTICALS LIMITED
ABN	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr David Foster
Date of last notice	5 November 2025

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Terry Foster + Ms Vickey S Foster - beneficiary Citicorp Nominees Pty Limited – beneficiary Citicorp Nominees Pty Limited – beneficiary
Date of change	12 November 2025
No. of securities held prior to change	
David Foster	• 6,306,829 fully paid ordinary shares • 4,000,000 options exercisable at $0.15 expiring 10 December 2027, vesting 50% on 10 December 2025 (12 months) and 50% on 10 December 2026 (24 months)
Mr Terry Foster + Ms Vickey S Foster <Foster Living Account>	• 126,328 fully paid ordinary shares
Citicorp Nominees Pty Limited	• 71,303 fully paid ordinary shares

Class	Options exercisable at $0.30 expiring 3 years from the Grant date (27 October 2028), vesting 50% on receipt of U.S. Food and Drug Administration approval for Galidesivir under the Animal Rule Pathway and 50% on issue of a Priority Review Voucher by the FDA in connection with such approval.
Number acquired	2,000,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$200
No. of securities held after change David Foster Mr Terry Foster + Ms Vickey S Foster <Foster Living Account> Citicorp Nominees Pty Limited	• 6,306,829 fully paid ordinary shares • 4,000,000 options exercisable at $0.15 expiring 10 December 2027, vesting 50% on 10 December 2025 (12 months) and 50% on 10 December 2026 (24 months) • 2,000,000 options exercisable at $0.30 expiring 3 years from the Grant date (27 October 2028), vesting 50% on receipt of U.S. Food and Drug Administration approval for Galidesivir under the Animal Rule Pathway and 50% on issue of a Priority Review Voucher by the FDA in connection with such approval. • 126,328 fully paid ordinary shares • 71,303 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options approved by Shareholders at Annual General Meeting on 9 October 2025

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ISLAND PHARMACEUTICALS LIMITED
ABN	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jason Alan Carroll
Date of last notice	25 July 2025

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	12 November 2025
No. of securities held prior to change Jason Alan Carroll	31,100,000 - fully paid ordinary shares 974,930 options exercisable at $0.07 expiring 4 December 2025 974,931 options exercisable at $0.07 expiring 4 December 2026

Class	i) Options exercisable at $0.30 expiring 3 years from the Grant date (27 October 2028), vesting 50% on receipt of U.S. Food and Drug Administration approval for Galidesivir under the Animal Rule Pathway and 50% on issue of a Priority Review Voucher by the FDA in connection with such approval. ii) Options exercisable at $0.15 expiring 3 years from the Grant date (27 October 2028), vesting 50% on 27 October 2026 (12 months) and 50% on 27 October 2027 (24 months)
Number acquired	i) 2,000,000 ii) 3,000,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	i) $200 ii) $300
No. of securities held after change Lynch Thinking Investments Pty Ltd	31,100,000 - fully paid ordinary shares 974,930 options exercisable at $0.07 expiring 4 December 2025 974,931 options exercisable at $0.07 expiring 4 December 2026 2,000,000 options exercisable at $0.30 expiring 3 years from the Grant date (27 October 2028), vesting 50% on receipt of U.S. Food and Drug Administration approval for Galidesivir under the Animal Rule Pathway and 50% on issue of a Priority Review Voucher by the FDA in connection with such approval. 3,000,000 options exercisable at $0.15 expiring 3 years from the Grant date (27 October 2028), vesting 50% on 27 October 2026 (12 months) and 50% on 27 October 2027 (24 months)

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	i) Options approved by Shareholders at Annual General Meeting on 9 October 2025 – Resolution 12 ii) Options approved by Shareholders at Annual General Meeting on 9 October 2025 – Resolution 13

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.